Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. Keeping that in mind, here are three small-cap stocks to avoid and some other investments you should consider instead.

Paramount (PARA)

Market Cap: $8.40 billion

Owner of Spongebob Squarepants and formerly known as ViacomCBS, Paramount Global (NASDAQ:PARA) is a major media conglomerate offering television, film production, and digital content across various global platforms.

Why Do We Steer Clear of PARA?

Annual revenue declines of 2.3% over the last two years indicate problems with its market positioning Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 23.5% annually Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Paramount is trading at $11.81 per share, or 7.9x forward P/E. Dive into our free research report to see why there are better opportunities than PARA.

Silgan Holdings (SLGN)

Market Cap: $5.82 billion

Established in 1987, Silgan Holdings (NYSE:SLGN) is a supplier of rigid packaging for consumer goods products, specializing in metal containers, closures, and plastic packaging.

Why Is SLGN Risky?

Annual sales declines of 3% for the past two years show its products and services struggled to connect with the market during this cycle Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term

Silgan Holdings’s stock price of $54.38 implies a valuation ratio of 13.1x forward P/E. If you’re considering SLGN for your portfolio, see our FREE research report to learn more.

Enovis (ENOV)

Market Cap: $2.07 billion

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Do We Avoid ENOV?

Sales tumbled by 9.1% annually over the last five years, showing market trends are working against its favor during this cycle Negative returns on capital show management lost money while trying to expand the business, and its falling returns suggest its earlier profit pools are drying up Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

Story Continues

At $36.22 per share, Enovis trades at 11x forward P/E. Read our free research report to see why you should think twice about including ENOV in your portfolio, it’s free.

Stocks We Like More

Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.

While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free.

View Comments